Comparison of the Uptake of Hepatocellular Carcinoma on Pre-Therapeutic MDCT, CACT, and SPECT/CT, and the Correlation with Post-Therapeutic PET/CT in Patients Undergoing Selective Internal Radiation Therapy

(1) Background: To comparatively analyze the uptake of hepatocellular carcinoma (HCC) on pre-therapeutic imaging modalities, the arterial phase multi-detector computed tomography (MDCT), the parenchymal phase C-arm computed tomography (CACT), the Technetium99m-macroaggregates of human serum albumin single-photon emission computed tomography/computed tomography (SPECT/CT), and the correlation to the post-therapeutic Yttrium90 positron emission tomography/computed tomography (PET/CT) in patients with selective internal radiation therapy (SIRT). (2) Methods: Between September 2013 and December 2016, 104 SIRT procedures were performed at our institution in 74 patients with HCC not suitable for curative surgery or ablation. Twenty-two patients underwent an identical sequence of pre-therapeutic MDCT, CACT, SPECT/CT, and post-therapeutic PET/CT with a standardized diagnostic and therapeutic protocol. In these 22 patients, 25 SIRT procedures were evaluated. The uptake of the HCC was assessed using tumor-background ratio (TBR). Therefore, regions of interest were placed on the tumor and the adjacent liver tissue on MDCT (TBRMDCT), CACT (TBRCACT), SPECT/CT (TBRSPECT/CT), and PET/CT (TBRPET/CT). Comparisons were made with the Friedman test and the Nemenyi post-hoc test. Correlations were analyzed using Spearman’s Rho and the Benjamini–Hochberg method. The level of significance was p < 0.05. (3) Results: TBR on MDCT (1.4 ± 0.3) was significantly smaller than on CACT (1.9 ± 0.6) and both were significantly smaller compared to SPECT/CT (4.6 ± 2.0) (pFriedman-Test < 0.001; pTBRMDCT/TBRCACT = 0.012, pTBRMDCT/TBRSPECT/CT < 0.001, pTBRCACT/TBRSPECT/CT < 0.001). There was no significant correlation of TBR on MDCT with PET/CT (rTBRMDCT/TBRPET/CT = 0.116; p = 0.534). In contrast, TBR on CACT correlated to TBR on SPECT/CT (rTBRCACT/TBRSPECT/CT = 0.489; p = 0.004) and tended to correlate to TBR on PET/CT (rTBRCACT/TBRPET/CT =0.365; p = 0.043). TBR on SPECT/CT correlated to TBR on PET/CT (rTBRSPECT/CT/TBRPET/CT = 0.706; p < 0.001) (4) Conclusion: The uptake assessment on CACT was in agreement with SPECT/CT and might be consistent with PET/CT. In contrast, MDCT was not comparable to CACT and SPECT/CT, and had no correlation with PET/CT due to the different application techniques. This emphasizes the value of the CACT, which has the potential to improve the dosimetric assessment of the tumor and liver uptake for SIRT.

[1]  L. Bordenave,et al.  Comparison of perfused volume segmentation between cone-beam CT and 99mTc-MAA SPECT/CT for treatment dosimetry before selective internal radiation therapy using 90Y-glass microspheres. , 2020, Diagnostic and interventional imaging.

[2]  P. O’Connor,et al.  Feasibility of Yttrium-90 Radioembolization Dose Calculation Utilizing Intra-procedural Open Trajectory Cone Beam CT , 2019, CardioVascular and Interventional Radiology.

[3]  H. Amthauer,et al.  Impact of combined selective internal radiation therapy and sorafenib on survival in advanced hepatocellular carcinoma. , 2019, Journal of hepatology.

[4]  S. Kappadath,et al.  Quantification of the inherent radiopacity of glass microspheres for precision dosimetry in yttrium-90 radioembolization , 2019, Biomedical Physics & Engineering Express.

[5]  S. Vauclin,et al.  Analysis of differences between 99mTc-MAA SPECT- and 90Y-microsphere PET-based dosimetry for hepatocellular carcinoma selective internal radiation therapy , 2019, EJNMMI Research.

[6]  David M. Liu,et al.  Y90 Radioembolization Dosimetry: Concepts for the Interventional Radiologist. , 2019, Techniques in vascular and interventional radiology.

[7]  J. Nuyts,et al.  Multi-modal image analysis for semi-automatic segmentation of the total liver and liver arterial perfusion territories for radioembolization , 2019, EJNMMI Research.

[8]  K. Unger,et al.  Comparison of Cone-Beam Tomography and Cross-Sectional Imaging for Volumetric and Dosimetric Calculations in Resin Yttrium-90 Radioembolization , 2018, CardioVascular and Interventional Radiology.

[9]  V. Gebski,et al.  SIRveNIB: Selective Internal Radiation Therapy Versus Sorafenib in Asia-Pacific Patients With Hepatocellular Carcinoma. , 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  Rachida Lebtahi,et al.  Efficacy and safety of selective internal radiotherapy with yttrium-90 resin microspheres compared with sorafenib in locally advanced and inoperable hepatocellular carcinoma (SARAH): an open-label randomised controlled phase 3 trial. , 2017, The Lancet. Oncology.

[11]  A. Schenk,et al.  Predictive SIRT dosimetry based on a territorial model , 2017, EJNMMI Physics.

[12]  D. Ganger,et al.  Same-day 90Y radioembolization: implementing a new treatment paradigm , 2016, European Journal of Nuclear Medicine and Molecular Imaging.

[13]  H. Amthauer,et al.  Pharmacokinetics of 99mTc-MAA- and 99mTc-HSA-Microspheres Used in Preradioembolization Dosimetry: Influence on the Liver–Lung Shunt , 2016, The Journal of Nuclear Medicine.

[14]  F. Wacker,et al.  Parametric response mapping of contrast-enhanced biphasic CT for evaluating tumour viability of hepatocellular carcinoma after TACE , 2016, European Radiology.

[15]  Marcus Hacker,et al.  Predictive Value of 99mTc-MAA SPECT for 90Y-Labeled Resin Microsphere Distribution in Radioembolization of Primary and Secondary Hepatic Tumors , 2015, The Journal of Nuclear Medicine.

[16]  R. Salem,et al.  Outpatient single-session yttrium-90 glass microsphere radioembolization. , 2014, Journal of vascular and interventional radiology : JVIR.

[17]  K. Boudjema,et al.  Boosted selective internal radiation therapy with 90Y-loaded glass microspheres (B-SIRT) for hepatocellular carcinoma patients: a new personalized promising concept , 2013, European Journal of Nuclear Medicine and Molecular Imaging.

[18]  A. Jones,et al.  Evaluation of the potential utility of flat panel CT for quantifying relative contrast enhancement. , 2012, Medical physics.

[19]  H. Alkadhi,et al.  Liver perfusion imaging in patients with primary and metastatic liver malignancy: prospective comparison between 99mTc-MAA spect and dynamic CT perfusion. , 2012, Academic radiology.

[20]  J. Machac,et al.  Characterization of extrahepatic distribution of Tc-99m macroaggregated albumin in hepatic perfusion imaging studies prior to yttrium-90 microsphere therapy. , 2011, Cancer biotherapy & radiopharmaceuticals.

[21]  J. Bruix,et al.  Current Strategy for Staging and Treatment: The BCLC Update and Future Prospects , 2010, Seminars in liver disease.

[22]  Riccardo Lencioni,et al.  Modified RECIST (mRECIST) Assessment for Hepatocellular Carcinoma , 2010, Seminars in liver disease.

[23]  Frank K Wacker,et al.  Visualization of hypervascular liver lesions During TACE: comparison of angiographic C-arm CT and MDCT. , 2008, AJR. American journal of roentgenology.

[24]  M. Reiser,et al.  Mid-term results in otherwise treatment refractory primary or secondary liver confined tumours treated with selective internal radiation therapy (SIRT) using 90Yttrium resin-microspheres , 2007, European Radiology.

[25]  Blanche Bapst,et al.  Cone Beam Computed Tomography (CBCT) in the Field of Interventional Oncology of the Liver , 2015, CardioVascular and Interventional Radiology.

[26]  A. Jones,et al.  Evaluation of the potential utility of flat panel CT for quantifying relative contrast enhancement. , 2012, Medical physics.